CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

  • Current Quote
  • Stock Chart
$3.89 + 0.01 (0.26%)
Day High:$3.90
Day Low:$3.82
04/20/184:00 p.m. ET
Delayed at least 15 minutes.

Ed Bell
T +1 206-272-4345


Recent News

Mar 09, 2018CTI BioPharma to Present at Upcoming Investor Conferences
SEATTLE, March 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present and host one-on-one meetings at the following investor conferences during the month of March: 30th Annual Roth Conference in Laguna Niguel, CA Date: Monday, March 12, 2018 Time: 8:30PM ET / 5:30PM PT Oppenheimer 28th Annual Healthcare Conference in New York, NY Date: Tuesday, March 20, 2018 Time: 10:55AM ET / 7:55AM PT 17th Annual Needham Health... 
Printer Friendly Version
Mar 09, 2018CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
SEATTLE, March 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that results from the Phase 3 PERSIST-2 clinical trial of pacritinib (an investigational JAK2 inhibitor) have been published online in JAMA Oncology. The randomized, international, multicenter study compared the efficacy and safety of pacritinib at two dose levels, compared with best available therapy (BAT), which included ruxolitinib (a JAK1/JAK2 inhibitor), in patients with myelofibrosis a... 
Printer Friendly Version
Mar 07, 2018CTI BioPharma Reports Fourth Quarter and Full Year 2017 Financial Results
-Management to Host Conference Call/ Webcast Today at 4:30 p.m. Eastern Time- SEATTLE, March 7, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2017. Clinical / Regulatory In July 2017, the first patient was enrolled in PAC203, a Phase 2 clinical trial of pacritinib in patients with primary myelofibrosis who have failed prior ruxolitinib therapy and/or have thrombocytopenia, to evaluate t... 
Printer Friendly Version


There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.